The clinical impact of ICOS signal in colorectal cancer patients

References

• Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002; 2:116-26; PMID:11910893; http://dx.doi.org/10.1038/nri727
   PubMed Web of Science ®Google Scholar
• Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol 2013; 34:556-63; PMID:23954143; http://dx.doi.org/10.1016/j.it.2013.07.003
   PubMed Web of Science ®Google Scholar
• Swallow MM, Wallin JJ, Sha WC. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity 1999; 11:423-32; PMID:10549624; http://dx.doi.org/10.1016/S1074-7613(00)80117-X
   PubMed Web of Science ®Google Scholar
• Faget J, Bendriss-Vermare N, Gobert M, Durand I, Olive D, Biota C, Bachelot T, Treilleux I, Goddard-Leon S, Lavergne E et al. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. Cancer Res 2012; 72:6130-41; PMID:23026134; http://dx.doi.org/10.1158/0008-5472.CAN-12-2409
   PubMed Web of Science ®Google Scholar
• Faget J, Sisirak V, Blay JY, Caux C, Bendriss-Vermare N, Menetrier-Caux C. ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4 T cells by plasmacytoid dendritic cells. Oncoimmunology 2013; 2:e23185; http:dx.doi.org/10.4161/onci.23185
   PubMed Web of Science ®Google Scholar
• Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraf R, Anagnostopoulos I, Kroczek RA. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 397:263-6; PMID:9930702; http://dx.doi.org/10.1038/16717
   PubMed Web of Science ®Google Scholar
• Coyle AJ, Lehar S, Lloyd C, Tian J, Delaney T, Manning S, Nguyen T, Burwell T, Schneider H, Gonzalo JA et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 2000; 13:95-105; PMID:10933398; http://dx.doi.org/10.1016/S1074-7613(00)00011-X
   PubMed Web of Science ®Google Scholar
• Yao S, Zhu Y, Zhu G, Augustine M, Zheng L, Goode DJ, Broadwater M, Ruff W, Flies S, Xu H et al. B7-h2 is a costimulatory ligand for CD28 in human. Immunity 2011; 34:729-40; PMID:21530327; http://dx.doi.org/10.1016/j.immuni.2011.03.014
   PubMed Web of Science ®Google Scholar
• Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013; 49:2233-42; PMID:23478000; http://dx.doi.org/10.1016/j.ejca.2013.02.015
   PubMed Web of Science ®Google Scholar
• Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G. Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol 2003; 46:33-57; PMID:12672517; http://dx.doi.org/10.1016/S1040-8428(02)00159-2
   PubMed Web of Science ®Google Scholar
• McAdam AJ, Chang TT, Lumelsky AE, Greenfield EA, Boussiotis VA, Duke-Cohan JS, Chernova T, Malenkovich N, Jabs C, Kuchroo VK et al. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J Immunol 2000; 165:5035-40; PMID:11046032; http://dx.doi.org/10.4049/jimmunol.165.9.5035
   PubMed Web of Science ®Google Scholar
• Detheux M, Standker L, Vakili J, Munch J, Forssmann U, Adermann K, Pohlmann S, Vassart G, Kirchhoff F, Parmentier M et al. Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties. J Exp Med 2000; 192:1501-8; PMID:11085751; http://dx.doi.org/10.1084/jem.192.10.1501
   PubMed Web of Science ®Google Scholar
• Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5:1365-9; PMID:10581077; http://dx.doi.org/10.1038/70932
   PubMed Web of Science ®Google Scholar
• Yoshinaga SK, Whoriskey JS, Khare SD, Sarmiento U, Guo J, Horan T, Shih G, Zhang M, Coccia MA, Kohno T et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature 1999; 402:827-32; PMID:10617205; http://dx.doi.org/10.1038/45582
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lv D, Kim HJ, Kurt RA, Bu W, Li Y, Ma X. A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells. Cell Res 2013; 23:394-408; PMID:23266888; http://dx.doi.org/10.1038/cr.2012.178
   PubMed Web of Science ®Google Scholar
• Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002; 20:29-53; PMID:11861596; http://dx.doi.org/10.1146/annurev.immunol.20.091101.091806
   PubMed Web of Science ®Google Scholar
• Mages HW, Hutloff A, Heuck C, Buchner K, Himmelbauer H, Oliveri F, Kroczek RA. Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand. Eur J Immunol 2000; 30:1040-7; PMID:10760791; http://dx.doi.org/10.1002/(SICI)1521-4141(200004)30:4<1040::AID-IMMU1040>3.0.CO;2-6
   PubMed Web of Science ®Google Scholar
• Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 1996; 4:535-43; PMID:8673700; http://dx.doi.org/10.1016/S1074-7613(00)80480-X
   PubMed Web of Science ®Google Scholar
• Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405-13; PMID:7882171; http://dx.doi.org/10.1016/1074-7613(94)90071-X
   PubMed Web of Science ®Google Scholar
• Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996; 183:2541-50; PMID:8676075; http://dx.doi.org/10.1084/jem.183.6.2541
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192(7):1027-34; PMID:11015443; http://dx.doi.org/10.1084/jem.192.7.1027
   PubMed Web of Science ®Google Scholar
• Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2:261-8; PMID:11224527; http://dx.doi.org/10.1038/85330
   PubMed Web of Science ®Google Scholar
• Sauter G, Simon R, Hillan K. Tissue microarrays in drug discovery. Nat Rev Drug Discov 2003; 2:962-72; PMID:14654795; http://dx.doi.org/10.1038/nrd1254
   PubMed Web of Science ®Google Scholar